Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

老虎证券2026/05/31 12:25

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The results of this study have been described as unprecedented, marking significant progress in the treatment of this hard-to-treat cancer.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

You may also like

Trending news

Crypto prices